Lupin has informed that it has enclosed a Press Release as regards launch by the Company of Tavaborole Topical Solution, 5% in the US, having received an approval from the US FDA. This considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.